Cytek Biosciences

Cytek Biosciences, Inc. is a life sciences technology company engaged in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in December 2014 and is headquartered in Fremont, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cytek Biosciences reports robust earnings, eyes growth through acquisitions

Cytek Biosciences delivered strong financial results in Q4 2022 and full year 2022, driven by revenue growth, strategic partnerships, and acquisitions.
The company's focus on revenue diversification, technological enhancements, and operational efficiencies positions it for continued growth and innovation in 2023.
While facing integration and operational challenges, Cytek remains optimistic about revenue growth, market expansion, and service margin improvements in the coming year.

Cytek Biosciences reports mixed Q1 results, eyes strategic growth

Cytek Biosciences saw mixed Q1 performance with revenue growth from acquisitions but organic revenue decline.
Strategic partnerships and product launches are strengthening Cytek's position in the market.
Challenges in revenue growth and increased expenses highlight the need for operational efficiency.
Despite financial setbacks, Cytek remains optimistic about future growth opportunities and market leadership.

Cytek Biosciences reports strong Q2 earnings, eyes growth opportunities

Cytek Biosciences delivered a robust performance in Q2 2023, marked by strong revenue growth and operational efficiency despite increased expenses.
The company's strategic focus on driving growth through acquisitions, technology advancements, and market opportunities bodes well for future expansion.
While challenges in managing expenses persist, Cytek's solid financial position and confidence in addressing market needs position it for sustained growth.
With a clear roadmap for growth and a talented team, Cytek remains poised to capitalize on opportunities and enhance shareholder value.

Cytek Biosciences reports solid Q3 growth and eyes global expansion

Cytek Biosciences delivered strong Q3 results with revenue growth and strategic focus on key pillars.
Despite challenges in sales cycles and order delays, the company remains innovative and responsive in the market.
Opportunities in new product launches, bioinformatics, and clinical markets provide avenues for future growth.
Cytek's performance reflects resilience amidst industry challenges and a commitment to driving innovation and expansion.

Cytek Biosciences reports robust Q4 earnings, eyes growth opportunities

Cytek Biosciences delivered strong financial results in Q4 2023, driven by revenue growth and operational efficiency, with a focus on profitability and innovation.
The company faces challenges in managing expenses, stabilizing revenue in key markets, and balancing new product contributions with cost control measures.
Opportunities lie in capitalizing on revenue outlook, expanding in the biotech segment, leveraging regional growth, and diversifying revenue streams.
Strategic planning and execution will be crucial for Cytek Biosciences to navigate challenges and maximize opportunities for sustainable growth and market leadership.

Cytek Biosciences reports strong Q1 growth amidst global market expansion

Cytek Biosciences' Q1 2024 performance reflects solid revenue growth and market expansion efforts.
While facing challenges in certain regions, the company is leveraging opportunities in product innovation and global demand.
Maintaining financial discipline and focusing on operational efficiency will be key to achieving profitability and sustained growth.

Cytek Biosciences reports Q2 revenue growth, eyes global expansion

Cytek Biosciences showed mixed performance in Q2 2024 with revenue growth in EMEA and APAC but a decline in the U.S., particularly in academic and government sectors.
The company's focus on key growth pillars and new capabilities like the ESP module, along with strategic initiatives like Cytek Cloud, positions it for future growth.
While facing challenges in the U.S. market, Cytek Biosciences aims to drive sustainable growth and profitability through cost control and revenue enhancement strategies.

Cytek Biosciences reports strong Q3 earnings, eyes global expansion

Cytek Biosciences demonstrated solid financial performance in Q3 2024, driven by revenue growth and effective expense management.
The company's strategic focus on key pillars and expanding user base positions it well for future success and market leadership.
While facing challenges in balancing investments and income, Cytek has opportunities to capitalize on global growth and market trends.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in 1992 and is headquartered in Fremont, CA.

The Cytek Reveal Roadshow Will Provide Insights to Accelerate Discoveries – from Basic Science to Highly Complex Assays The Cytek Reveal Roadshow Will Provide Insights to Accelerate Discoveries – from Basic Science to Highly Complex Assays

Cytek® Biosciences Launches Educational Roadshow Focused on Spectral Flow Cytometry

FREMONT, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York, New York.

Cytek Biosciences to participate in the Morgan Stanley 21st Annual Global Healthcare Conference

FREMONT, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the appointment of Philippe Busque, Ph.D.

Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services

Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2023 Results Conference Call August 8, 2023 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO Patrik Jeanmonod - CFO Conference Call Participants Steven Mah - TD Cowen David Westenberg - Piper Sandler Operator Good day, and thank you for standing by. Welcome to the Cytek Biosciences Second Quarter 2023 Earnings Conference Call.

Cytek Biosciences, Inc. (CTKB) Q2 2023 Earnings Call Transcript

FREMONT, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 2023 UBS MedTech, Tools and Genomics Summit in Dana Point, CA.

Cytek Biosciences to Participate in the UBS MedTech, Tools and Genomics Summit

Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.03 per share a year ago.

Cytek Biosciences, Inc. (CTKB) Q2 Earnings Lag Estimates

FREMONT, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2023.

Cytek Biosciences Reports Second Quarter 2023 Financial Results

FREMONT, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the second quarter 2023 after market close on Tuesday, August 8th, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Cytek Biosciences to Report Second Quarter 2023 Financial Results on August 8, 2023

FREMONT, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 44th Annual Goldman Sachs Healthcare Conference in Dana Point, CA.

Cytek Biosciences to Participate in the 44th Annual Goldman Sachs Healthcare Conference

FREMONT, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law. The Company's common stock is listed on The Nasdaq Global Select Market under the symbol “CTKB”. The repurchase program will continue until the end of the fiscal year unless extended or shortened by the Board of Directors.

Cytek Biosciences Announces $50 Million Stock Repurchase Program

FREMONT, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that it has shipped its 100th Cytek Aurora CS system. This milestone is a clear indication of the company's continuing momentum – and of the scientific community's desire for Full Spectrum Profiling™ (FSP™) technology that streamlines workflows, accelerates discoveries and maximizes efficiency.

Cytek® Biosciences Marks Shipment of Its 100th Cell Sorter as the Company Continues to Lead Cell Analysis Forward

Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Paul Goodson - Head Investor Relations Wenbin Jiang - Chief Executive Officer Patrik Jeanmonod - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler Stephanie Yan - TD Cowen Operator Good afternoon, and thank you for standing by. Welcome to the Cytek Biosciences First Quarter 2023 Earnings Conference Call.

Cytek Biosciences, Inc. (CTKB) Q1 2023 Earnings Call Transcript

Cytek focuses on cell analysis primarily for research purposes. The company joined the S&P SmallCap 600 Index last month.

Why Shares of Cytek Biosciences Dropped This Week

Cytek Biosciences, Inc. (CTKB) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.01 per share a year ago.

Cytek Biosciences, Inc. (CTKB) Reports Break-Even Earnings for Q1

FREMONT, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the first quarter ended March 31, 2023.

Cytek Biosciences Reports First Quarter 2023 Financial Results

Cytek Biosciences, Inc. (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Cytek Biosciences, Inc. (CTKB) Soars 13.4%: Is Further Upside Left in the Stock?

FREMONT, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2023 after market close on Tuesday, May 9th, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Cytek Biosciences to Report First Quarter 2023 Financial Results on May 9, 2023

Cytek Biosciences, Inc. (CTKB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why Cytek Biosciences, Inc. (CTKB) is Poised for a Turnaround After Losing -16.6% in 4 Weeks

Optimized for Cytek Cell Analysis Systems; Single-Tube Panel Accelerates Acute Myeloid Leukemia Research and MRD Detection Optimized for Cytek Cell Analysis Systems; Single-Tube Panel Accelerates Acute Myeloid Leukemia Research and MRD Detection

Cytek® Biosciences Introduces New 20-Color AML Panel

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 40% and 3.07%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Q4 Earnings Top Estimates

Full year 2022 revenue increased 28%, or 34% on constant currency basis, compared to prior year

Cytek Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results

SALUGGIA, Italy, and FREMONT, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has completed the sale of substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit to Cytek for approximately USD 46.5 million.

Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed

SALUGGIA, Italy and FREMONT, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit. The sale is expected to close within 30 days, subject to customary closing conditions.

Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin

FREMONT, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, February 28th, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Cytek Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023

New Agreement Enhances High-Parameter Panels on Cytek Cell Analysis Systems New Agreement Enhances High-Parameter Panels on Cytek Cell Analysis Systems

News for Cytek Biosciences Stock (CTKB)